Feasibility and Safety of Ex Vivo Delivery of Rituximab to Lung Allografts in Transplant Recipients at High Risk for Epstein-Barr Virus–associated Posttransplant Lymphoproliferative Disorder
EVLP-based rituximab delivery is a feasible and promising strategy for targeting donor-transmitted EBV with minimal systemic exposure. Although the findings suggest potential clinical benefit, the development of PTLD in extrathoracic sites underscores the need for further optimization and larger studies to evaluate efficacy and refine the intervention.
Authors
- Atul Humar (ORCID: https://orcid.org/0000-0002-1751-7159)
- Matthew Ierullo (ORCID: https://orcid.org/0000-0001-9638-873X)
- Victor H. Ferreira (ORCID: https://orcid.org/0000-0002-1472-9711)
- Aizhou Wang (ORCID: https://orcid.org/0000-0002-4684-9929)
- Lianne Gail Singer (ORCID: https://orcid.org/0000-0002-2693-8676)
- Deepali Kumar (ORCID: https://orcid.org/0000-0003-1961-0477)
- Beata Majchrzak-Kita (ORCID: https://orcid.org/0000-0001-5634-1443)
- Rafaela Vanin Pinto Ribeiro (ORCID: https://orcid.org/0000-0002-5627-9157)
- Shaf Keshavjee (ORCID: https://orcid.org/0000-0003-4547-8094)
- Marcelo Cypel (ORCID: https://orcid.org/0000-0001-5652-1938)
- Faranak Mavandadnejad
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Toronto General Hospital (CA)
- Toronto General Hospital Research Institute
Publication Details
- Journal
- Transplantation Direct
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1097/txd.0000000000001784
- Citations
- 1
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01